Health Canada approves AbbVie’s Elahere for ovarian cancer
Health Canada has approved AbbVie's antibody-drug conjugate (ADC), Elahere (mirvetuximab soravtansine for injection), to treat adults with certain types of…
Health Canada has approved AbbVie's antibody-drug conjugate (ADC), Elahere (mirvetuximab soravtansine for injection), to treat adults with certain types of…
China's National Medical Products Administration (NMPA) has granted conditional approval to Boehringer Ingelheim's Hernexeos (zongertinib tablets), for use as a…
Amphastar Pharmaceuticals has signed an exclusive licence agreement with Nanjing Anji Biotechnology, focusing on the development, production, use and commercialisation…
Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food and Drug…
Genmab and AbbVie’s subcutaneous bispecific antibody Epkinly (epcoritamab) has met its dual primary endpoints as a second-line combination therapy in…
The US Food and Drug Administration (FDA) has given accelerated approval to Jazz Pharmaceuticals for Modeyso (dordaviprone) to treat adults…
Oncology company BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation from the European…
Contract development and manufacturing organisation ViroCell Biologics has partnered AvenCell Therapeutics for expediting the development of new allogeneic chimeric antigen…
The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, lenalidomide and dexamethasone…
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…